Xencor, Inc splits its revenue into 5 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Royalty at $80.3 million, 64% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 31, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
200
|
126
|
110
|
175
|
165
|
275
|
123
|
157
|
41
|
—
|
—
|
| Royalty |
156
+103.0%
share 77.6%
|
80
+18.9%
share 63.9%
|
67
+21.0%
share 61.1%
|
56
-63.3%
share 32.0%
|
152
+89.4%
share 92.4%
|
80
+351.1%
share 29.2%
|
18
+256.0%
share 14.5%
|
5
share 3.2%
|
—
|
—
|
—
|
| Non Cash Royalties |
—
|
—
|
67
+358.2%
share 60.5%
|
15
share 8.4%
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Milestone |
45
-39.0%
share 22.3%
|
45
+31.3%
share 36.1%
|
34
-61.0%
share 31.2%
|
88
+1509.1%
share 50.7%
|
6
-73.8%
share 3.3%
|
21
-58.2%
share 7.6%
|
50
+116.4%
share 40.9%
|
23
+13.2%
share 14.8%
|
20
-21.2%
share 50.5%
|
26
|
—
|
| Collaboration |
—
|
—
|
—
|
30
+333.1%
share 17.4%
|
7
-92.5%
share 4.3%
|
93
+1966.7%
share 33.8%
|
4
-72.4%
share 3.7%
|
16
-18.9%
share 10.4%
|
20
+0.0%
share 49.5%
|
20
|
—
|
| License |
—
|
—
|
8
share 7.7%
|
—
|
—
|
81
+61.0%
share 29.4%
|
50
-55.3%
share 40.9%
|
112
share 71.6%
|
—
|
0
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- XNCR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Pasadena, CA
- SEC filer status
- Accelerated filer
- SEC CIK
- 1326732
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.